Insulin Price and Availability Survey in Pakistan Post-Deregulation

Encompassing survey data from 30 retail pharmacies across six regions in Pakistan, analyzing the impact of a price deregulation policy on insulin access. It includes standardized consumer prices, product availability percentages, and affordability measured in days' wages for the lowest-paid worker. The analysis compares price changes between non-NEML and NEML-listed insulin products.

Use Cases

• Analyze price changes between non-NEML and NEML-listed insulin products using standardized 10 ml prices.
• Compare availability percentages of originator brands versus biosimilar insulins for human and analogue types.
• Calculate the affordability impact by modeling the median number of days' wages required for a month's insulin supply.
• Perform a difference-in-differences analysis on insulin price data before and after the deregulation policy.

Strengths

• Data is based on a structured survey of 30 retail pharmacies across six regions in Pakistan.
• Includes specific price change metrics, such as a median price increase of 31.87% post-deregulation.
• Provides detailed availability percentages, such as 78.0% for human originator brand insulins.

Limitations

• The dataset is small at 5.5 KB, indicating limited scope and likely a small number of observations.
• Geographic coverage is limited to six regions within Pakistan, which may not be nationally representative.
• Temporal coverage is focused on a specific policy change period, limiting longitudinal analysis.

Provenance

Source

Survey conducted by author Amna Saeed, published on figshare.

Collection Method

Data collected via an adapted WHO/HAI survey approach from 30 retail pharmacies; pre-deregulation prices extracted from published sources.

Time Range

Covers periods before and after the implementation of a price deregulation policy.

Freshness

Last updated in March 2026.

Geography

Pakistan, specifically six surveyed regions.